Literature DB >> 20675982

Improving cardiovascular risk reduction for primary prevention--utility of lifetime risk assessment.

Kurt S Elward1, Ross J Simpson, Phil Mendys.   

Abstract

The objective of this article is to review the evidence basis for short-term risk assessments of overall coronary heart disease (CHD) burden as compared with lifetime risk estimates of CHD, based on the current medical literature. We reviewed literature published in the last 6 years using the terms "cardiovascular prevention," "Framingham risk scoring," "lifetime risk," and "cardiovascular risk assessment," and subsequently evaluated 98 publications to determine the variation in these approaches to estimate cardiovascular risk factors and impact on clinical decision making. The current evidence base suggests that lifetime risk estimates offset the significant impact of age on traditional, short-term risk estimates of cardiovascular risk. We conclude that the use of lifetime risk estimates may be more clinically meaningful than traditional, short-term risk estimates to assess an individual's overall risk burden, and may prevent the potential delay of therapeutic interventions to reduce cardiovascular events. For primary care, this difference may be of relevance to patients and should be communicated to them.

Entities:  

Mesh:

Year:  2010        PMID: 20675982     DOI: 10.3810/pgm.2010.07.2186

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  7 in total

1.  [Clinical outcomes, health-related quality of life, and cost-effectiveness of a 6-month community- based lifestyle program for adults at increased cardiovascular risk in lower Austria].

Authors:  Ursula Reichenpfader; Kylie Thaler; Anke Richter; Patricia Thieda; Gerald Gartlehner
Journal:  Wien Med Wochenschr       Date:  2012-08-28

2.  Association of Cumulative Systolic Blood Pressure With Long-Term Risk of Cardiovascular Disease and Healthy Longevity: Findings From the Lifetime Risk Pooling Project Cohorts.

Authors:  Orna Reges; Hongyan Ning; John T Wilkins; Colin O Wu; Xin Tian; Michael J Domanski; Donald M Lloyd-Jones; Norrina B Allen
Journal:  Hypertension       Date:  2020-12-21       Impact factor: 10.190

3.  Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database.

Authors:  Julia Hippisley-Cox; Carol Coupland; John Robson; Peter Brindle
Journal:  BMJ       Date:  2010-12-09

4.  Time-to-event versus ten-year-absolute-risk in cardiovascular risk prevention - does it make a difference? Results from the Optimizing-Risk-Communication (OptRisk) randomized-controlled trial.

Authors:  Charles Christian Adarkwah; Nikita Jegan; Monika Heinzel-Gutenbrunner; Felicitas Kühne; Uwe Siebert; Uwe Popert; Norbert Donner-Banzhoff; Sarah Kürwitz
Journal:  BMC Med Inform Decis Mak       Date:  2016-11-29       Impact factor: 2.796

5.  The effect of a new lifetime-cardiovascular-risk display on patients' motivation to participate in shared decision-making.

Authors:  Nikita Roman A Jegan; Sarah Anna Kürwitz; Lena Kathrin Kramer; Monika Heinzel-Gutenbrunner; Charles Christian Adarkwah; Uwe Popert; Norbert Donner-Banzhoff
Journal:  BMC Fam Pract       Date:  2018-06-09       Impact factor: 2.497

6.  The Optimizing-Risk-Communication (OptRisk) randomized trial - impact of decision-aid-based consultation on adherence and perception of cardiovascular risk.

Authors:  Charles Christian Adarkwah; Nikita Jegan; Monika Heinzel-Gutenbrunner; Felicitas Kühne; Uwe Siebert; Uwe Popert; Norbert Donner-Banzhoff; Sarah Kürwitz
Journal:  Patient Prefer Adherence       Date:  2019-03-27       Impact factor: 2.711

Review 7.  A systematic review of recent clinical practice guidelines on the diagnosis, assessment and management of hypertension.

Authors:  Lubna A Al-Ansary; Andrea C Tricco; Yaser Adi; Ghada Bawazeer; Laure Perrier; Mohammed Al-Ghonaim; Nada AlYousefi; Mariam Tashkandi; Sharon E Straus
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.